LUIS FONG: Open Payments
NPI 1598259467 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,855 in 69 payments from 11 companies in 2025. Trend: 2023 $14,100 · 2024 $6,363 · 2025 $6,855
Speaker / faculty: $5,500Food & beverage: $1,198Travel & lodging: $157
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $5,879 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $334 |
| Alkermes, Inc. | 6 | $250 |
| Neurocrine BioSciences, Inc. | 4 | $96 |
| Indivior Inc. | 3 | $84 |
| Sumitomo Pharma America, Inc. | 1 | $78 |
| E.R. Squibb & Sons, L.L.C. | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, LYBALVI, INGREZZA, SUBLOCADE, GEMTESA, COBENFY, Qelbree.
Industry payments across AZ — which companies pay providers there.
